Ñî¹óåú´«Ã½Ò•îl

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • Ñî¹óåú´«Ã½Ò•îl Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Thursday, Oct 22 2026 UPDATED 9:49 AM

Full Issue

Research Roundup: The Latest Science, Discoveries, And Breakthroughs

Each week, Ñî¹óåú´«Ã½Ò•îl Health News compiles a selection of health policy studies and briefs.

Researchers from the Rush Alzheimer’s Disease Center and other institutions examined, in extraordinary detail, brain tissue from 11 people who died at ages 80 to 91. They discovered that some particles had penetrated deep into the brain, reaching the amygdala, a region that helps shape emotion and memory. (Eunjung Cha, 10/22)

Presidential sessions at top cancer meetings typically feature practice-changing clinical trials, detailed in front of thousands of global experts packed into rooms so cavernous they merit their own ZIP codes. But last year, at the most important European oncology conference, one slot was reserved for a presentation of early results from a German biotech’s study of just 16 patients. (Joseph, 10/21)

People with aging-associated farsightedness gained a new topical treatment option as the FDA expanded the approval of phentolamine ophthalmic solution 0.75% (Ryzumvi) to include presbyopia, according to Opus Genetics and Viatris. The eye drops, designed to improve near vision while preserving distance vision, reduce pupillary dilation by means of a sympatholytic mechanism that does not involve the ciliary muscle. (Bankhead, 10/19)

Children and adolescents who received antibiotics had 1.5-times-higher odds of irritable bowel syndrome (IBS) by age 24 than those who had not, Swedish researchers reported today at the annual United European Gastroenterology (UEG) conference. The findings are from an analysis of 2,853 participants enrolled in the BAMSE study, which began in Stockholm in 1994 and was originally established to study environmental and nutritional factors involved in the development of allergies and other chronic conditions. (Dall, 10/19)

An emerging technique called spatial frequency domain imaging (SFDI) proved its mettle for evaluating skin fibrosis in systemic sclerosis (SSc), also called scleroderma, in an early clinical study. Comparing SFDI parameters with modified Rodnan Skin Score (mRSS) values and findings from histological biopsy analyses yielded correlations strong enough that the new approach deserves additional testing in larger samples, according to Andreea M. Bujor, MD, PhD, of Boston University (BU), and colleagues writing in Lancet Rheumatology. (Gever, 10/15)

In an "exceptionally" rare case, an infant was found to have a second colon, researchers reported. (Jeffrey, 10/19)

People who smoke or vape weed — but not those who use edibles — might need more anesthesia, researchers say. Weed smokers required substantially higher levels of the general anesthetic propofol than non-users during colonoscopy or upper endoscopy, researchers reported at the annual meeting of the American Society of Anesthesiologists. However, people who consumed weed edibles wound up requiring less anesthesia, researchers found. (Thompson, 10/19)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, October 22
  • Wednesday, October 21
  • Tuesday, October 20
  • Monday, October 19
  • Friday, October 16
  • Thursday, October 15
More Morning Briefings
RSS Feeds
  • Ñî¹óåú´«Ã½Ò•îl
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF